Finished
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
NCT02159703 · Abramson Cancer Center at Penn Medicine · Updated 21 Nov 2019
- What is being tested
- TORS; Adjuvant Radiation Therapy
- For
- Oropharyngeal Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 60 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started Feb 2014, ends Feb 2018. Registered 10 June 2014.
- Results
- Posted on the registry on 21 Nov 2019.
In the researchers' words
To determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx. To determine acute and long-term toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx.
Sites
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania, United States